From the boardroom to the body, health companies are rethinking how decisions get made.
Lululemon has a new CEO
The company named former Nike executive Heidi O’Neill to lead its next phase, stepping in after months of leadership uncertainty and mounting pressure from investors.
- The brand is dealing with slowing North American sales, rising competition, and margin pressure from tariffs costing $100M+.
- Meanwhile, founder Chip Wilson is actively pushing for board changes in an ongoing proxy battle, publicly criticizing the company’s direction and product strategy.
- Competition is rising, and the company still faces challenges in product and brand relevance.
Incumbents like lululemon will continue to face pressure to evolve as activewear shifts towards new entrants, faster product cycles, and performance-driven innovation.
OpenAI moves deeper into healthcare
The company launched ChatGPT for Clinicians, a version of its platform designed to support documentation, research, and clinical workflows, now available free to verified providers in the US.
- AI adoption is already widespread, with more than 70% of physicians reporting use in practice.
- The move puts OpenAI in more direct competition with companies like OpenEvidence, which reached a $12B valuation by positioning itself as a clinical decision-support tool.
As more clinicians lean on AI to relieve administrative burden, platforms like OpenAI are becoming a critical control point in the healthcare stack.
Ultrahuman links data x training
The company partnered with Les Mills to integrate biometric data from its ring into personalized workout recommendations inside its app.
- The new system adjusts training based on recovery, sleep, and physiological signals.
- Addressing gaps in the category, it translates data into decisions to align training with real-time physiology and daily programming.
In the budding wearables arms race, the value is shifting from tracking to intervention — turning data into behavior change.
